Connect with us

Press Releases

MYOS CORP Announces Positive Results from Mobility and Quality of Life Study

Dogs supplemented with fortetropin experienced statistically significant improvements in LOAD (Liverpool Osteoarthritis in Dogs) scores.

mm

Published

on

(PRESS RELEASE) CEDAR KNOLLS, NJ — MYOS Corp, a research-based advanced nutrition company with divisions that address both Human Nutrition and Animal Health announced its positive results from a randomized, double blind, placebo-controlled veterinary clinical study that it sponsored at Kansas State University to examine the impact of Fortetropin on the quality of life and mobility in geriatric dogs. 90% of dogs that are five years of age or older suffer from osteoarthritis, a painful condition that can severely impact their mobility and quality of gains in muscle tissue in multiple clinical studies involving humans. life. Fortetropin is an advanced nutrition product marketed by MYOS that has been shown to accelerate gains in muscle tissue in multiple clinical studies involving humans.

This most recent study completed at Kansas State University involved supplementing geriatric dogs with a nutrition product, with half of the dogs enrolled receiving Fortetropin and the other half of the dogs enrolled receiving a macronutrient-matched placebo. Dog owners were required to complete a standardized questionnaire called LOAD (Liverpool Osteoarthritis in Dogs). The LOAD questionnaire was developed and validated by veterinarians and veterinary researchers at the University of Liverpool, United Kingdom, and has been used extensively in clinical studies on canine osteoarthritis published in the peer-reviewed literature. The LOAD questionnaire is comprised of 13 questions that relate to general mobility in addition to the capability to perform exercise. Each question is assigned a score from 0 to 4 with higher scores corresponding to increased severity of osteoarthritis.

Advertisement

Promoted Headlines

Most Popular